An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America,…
VERDICT
The label
Accumulation
read at $60.58
Biomarin Pharmaceutical Inc holds its Accumulation at $60.58.
PHPhase · the trend structure carries the Accumulation label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-30
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 16 days
Price
$60.58
Valuation
43.58 trailing · 9.47 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.24
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$60.58
43.58 P/E · 9.47 fwd
Our fair value
$107.50
78% discount
Analyst target (avg)
$86.00
+42% to current
Target low $50.00Analyst target rangeTarget high $120.00
▲ current $60.58 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$60.58
you are here
Conservative
$105.51
+74%
Analyst avg
$86.00
+42%
Our fair value
$107.50
+77%
Analyst high
$120.00
+98%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
2.80%
Profit margin
8.29%
Debt to equity
23.17
Analyst consensus
Buy · 25 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is of its assets, above the one-third ceiling the screen allows.Fail
Interest-bearing cashInterest-bearing cash and securities are of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is of assets, above the 49% limit.Fail
Revenue purity of revenue comes from non-compliant sources, over the 5% line.Fail
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Rare Disease Biotech at a Discount Price
Picture a specialist biotech firm racing to treat rare diseases, yet posting just 3% revenue growth and an 8% profit margin. BioMarin trades at $59.59 with a forward P/E of 9.3x, but we pass. The narrow moat and 4% ROE signal limited ability to compound capital over time, even with an ethical screen pass and analyst targets around $86.
The 80% gap to our fair value of $107.50 looks tempting at first glance. Yet low single digit growth and thin returns on equity point to a business that struggles to scale its pipeline into durable profits. Consensus buy ratings do not change the underlying economics.
Risks centre on execution in a competitive rare disease space and the narrow moat that leaves room for rivals. Currency moves and regulatory setbacks could further pressure margins. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADER
The trader read · the latest dated commentary
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (26 analysts) rates it buy, with a mean price target of $88. Entered 2026-07-23 · Accumulation
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (26 analysts) rates it buy, with a mean price target of $88.
2026-07-18Markup$55.95+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (26 analysts) rates it buy, with a mean price target of $88.
2026-07-03Markup$55.95+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$55.95Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$52.58
+7.2%
·
$1,072
+7.2%
2 months
$54.53
+3.3%
·
$1,033
+3.3%
3 months
$59.07
-4.6%
·
$954
-4.6%
6 months
$52.99
+6.3%
·
$1,063
+6.3%
1 year
$57.48
-2.0%
·
$980
-2.0%
2 years
$82.94
-32.1%
·
$679
-32.1%
3 years
$91.37
-38.3%
·
$617
-38.3%
5 years
$82.07
-31.3%
·
$687
-31.3%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever BMRN does next, these words stay.
Biomarin Pharmaceutical Inc · BMRN · Accumulation · $60.58
Recorded 2026-07-30 · before the outcome · scored mechanically
